唑来膦酸联合吗啡缓释片治疗骨转移性疼痛  

Zoledronic Acid plus Morphine Hydrochloride Sustained-release Tablets in the Treatment of Bone Metastatic Pain

作　　者：张茹茹[1] 彭猛青[1] 朱杰[1] 郁飞文 

机构地区：[1]宿迁市钟吾医院肿瘤科,江苏宿迁223800

出　　处：《肿瘤基础与临床》2014年第6期504-506,共3页journal of basic and clinical oncology

摘　　要：目的观察唑来膦酸联合吗啡缓释片治疗恶性肿瘤患者骨转移性疼痛的临床疗效。方法应用唑来膦酸联合吗啡缓释片治疗恶性肿瘤骨转移性疼痛患者35例,治疗后2周评价疗效。结果 35例患者中,疼痛总有效率94.3%。KPS评分治疗前为(62.8±9.8)分,治疗后为(72.8±11.7)分,差异有统计学意义(P<0.05)。QOL评分治疗前(31.0±8.8)分,治疗后(45.1±6.4)分,差异有统计学意义(P<0.05)。结论唑来膦酸联合吗啡缓释片治疗恶性肿瘤骨转移性疼痛临床疗效显著,患者得到生活质量明显改善。Objective To observe the effect of zoledronic acid plus morphine hydrochloride sustained-release tablets in the treatment of bone metastatic pain of patients with malignant tumor. Methods Thirty-five cases of bone metastatic pain of patients with malignant tumor received the zoledronic acid plus morphine hydrochloride sustained-release tablets,and the effectiveness was evaluated after 2 weeks. Results Of the 35 cases,the total response rate was 94. 3%. KPS score was（62. 8 ± 9. 8）before treatment,and was（72. 8 ± 11. 7）after treatment（P〈0. 05）. TheQOLscorewas（31.0±8.8）beforetreatment,andwas（45.1±6.4）aftertreatment（P〈0.05）.Conclu-sion zole-dronic acid plus morphine hydrochloride sustained-release tablets has the good efficacy in the treatment of bone metastatic pain of patients with malignant tumor,and can improve the quality of life of.

关 键 词：唑来膦酸 吗啡缓释片 骨转移 疼痛 生活质量 

分 类 号：R730.6[医药卫生—肿瘤] R730.58[医药卫生—临床医学]